文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症监护病房代谢性酸中毒的碳酸氢钠给药:一项目标试验模拟

Sodium bicarbonate administration for metabolic acidosis in the intensive care unit: a target trial emulation.
PubMed 文献 · Intensive Care Med · 2025-06-10
一句话结论在12个澳大利亚ICU的回顾性目标试验模拟中,碳酸氢钠治疗与代谢性酸中毒患者30天ICU死亡率绝对降低1.9%相关(风险比0.86,95%CI 0.80-0.91)。

该研究为回顾性队列研究,采用目标试验模拟方法,纳入12个澳大利亚ICU中pH<7.3且PCO2≤45 mmHg的成人患者,排除重复入院、中毒、糖尿病酮症酸中毒及既往终末期肾衰竭。共6157例合格入院,其中1764例(29%)接受碳酸氢钠。主要分析显示碳酸氢钠治疗与30天ICU死亡率绝对降低1.9%相关(风险比0.86,95%CI 0.80-0.91),所有评估亚组均观察到显著获益。敏感性分析点估计为2.1%,30天时死亡率降低持续存在。结论认为该关联虽小但具统计学显著性,随机试验需大样本量才能证实。

要点

  • 在12个澳大利亚ICU的6157例pH<7.3且PCO2≤45 mmHg成人患者中,1764例(29%)接受碳酸氢钠,30天ICU死亡率绝对降低1.9%(风险比0.86,95%CI 0.80-0.91)。
  • 亚组分析(急性肾损伤、需要血管活性药物、pH<7.2)均显示显著获益。
  • 敏感性分析(滚动入组匹配)点估计为2.1%,30天死亡率降低持续存在。
  • 排除重复入院、中毒、糖尿病酮症酸中毒及既往终末期肾衰竭患者。
  • 作者认为随机试验需大样本量才能证实该效应。

适用人群与场景

  • 成人ICU患者,pH<7.3且PCO2≤45 mmHg(入住ICU前三天内)。
  • 排除:重复入院、中毒、糖尿病酮症酸中毒、既往终末期肾衰竭。

诊断标准与关键阈值

  • 代谢性酸中毒定义:pH<7.3且PCO2≤45 mmHg。

研究设计与关键结果

  • 回顾性队列研究,目标试验模拟,12个澳大利亚ICU,6157例合格入院,1764例(29%)接受碳酸氢钠。
  • 主要结局30天ICU死亡率(ICU出院为竞争事件):碳酸氢钠组绝对死亡率降低1.9%(风险比0.86,95%CI 0.80-0.91)。
  • 所有评估亚组(急性肾损伤、需要血管活性药物、pH<7.2)均显示显著获益。
  • 敏感性分析(滚动入组匹配)点估计为2.1%,30天死亡率降低持续存在。

证据类型、等级与局限

  • 证据类型:回顾性队列研究,目标试验模拟。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为碳酸氢钠给药与代谢性酸中毒患者30天ICU死亡率小幅但统计学显著降低相关。
  • 作者认为需大样本量随机试验才能证实该效应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Sodium bicarbonate is commonly administered to treat metabolic acidosis in intensive care units (ICUs). There is limited evidence from randomized trials to support this practice, and observational studies show conflicting results. Our aim was to perform a target trial emulation evaluating the effect of bicarbonate therapy on mortality.

METHODS: Retrospective cohort study using data from 12 Australian ICUs. Inclusion criteria were adults with pH < 7.3 and PCO2 ≤ 45 mmHg within the first three days. We excluded repeat admissions, toxicology, diabetic ketoacidosis, and pre-existing end-stage renal failure. The treatment intervention was sodium-bicarbonate administration, and the primary outcome was 30-day ICU mortality with ICU discharge as a competing event. We evaluated multiple subgroups, including patients with acute kidney injury, requirement for vasoactive therapy, and pH < 7.2. The primary model utilized a parametric g-computation and rolling entry matching was performed as a sensitivity analysis.

RESULTS: We identified 6157 eligible admissions, of which 1764 (29%) received sodium bicarbonate. Bicarbonate therapy was associated with a 1.9% absolute mortality reduction for the primary analysis [risk ratio 0.86, 95% confidence interval (CI) 0.80 to 0.91], and significant benefits were seen across all subgroups evaluated. A similar point estimate of 2.1% was observed in the sensitivity analysis, with a sustained mortality reduction seen at 30 days.

CONCLUSION: In this target trial emulation, bicarbonate administration was associated with a small but statistically significant reduction in mortality for patients with metabolic acidosis. Large sample sizes would be required to demonstrate this effect in a randomized trial.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Blank SP, Blank RM, Laupland KB, et al. Sodium bicarbonate administration for metabolic acidosis in the intensive care unit: a target trial emulation. Intensive Care Med. 2025. PMID: 40493225. doi:10.1007/s00134-025-07979-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。